Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile BRAF wild-type
Therapy Lenvatinib + Pembrolizumab
Indication/Tumor Type anaplastic thyroid carcinoma
Response Type sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
BRAF wild-type anaplastic thyroid carcinoma sensitive Lenvatinib + Pembrolizumab Phase II Actionable In a Phase II trial, treatment with Keytruda (pembrolizumab) and Lenvima (Lenvatinib) resulted in a median overall survival of 13 months, median progression-free survival of 5.4 months, and a best overall response rate of 36% (9/25, 1 complete, 8 partial responses) in patients with BRAF wild-type metastatic anaplastic thyroid cancer (PMID: 42673705; NCT04171622). 42673705
PubMed Id Reference Title Details
(42673705) Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial. Full reference...